Animal models have shown that the direct modulation of liver bile acid receptor function, by ER-β agonists, or indirect modulation, by adipose suppression, could provide therapeutic benefits for NASH [61]. This evidence concerns the gene ESR2 and metabolic dysfunction-associated steatohepatitis.